Evidence map›Paper›PMID 25579746›Full record

ReviewMolecular aspects of medicine2015

Immunogenetics of type 1 diabetes mellitus.

Michael P Morran, Andrew Vonberg, Anmar Khadra, Massimo Pietropaolo

Open access · greenAbstract readReview
In one paragraph

Review in Molecular aspects of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 159 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Genetic variants inFrontiers in endocrinology · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. International journal of molecular sciences · 2023
    Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Michael P MorranLaboratory of Immunogenetics, The Brehm Center for Diabetes Research, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Andrew VonbergLaboratory of Immunogenetics, The Brehm Center for Diabetes Research, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Anmar KhadraDepartment of Physiology, McGill University, Montreal, QC, Canada.
Massimo PietropaoloLaboratory of Immunogenetics, The Brehm Center for Diabetes Research, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA. Electronic address: Massimo.Pietropaolo@bcm.edu.
University of Michigan · USMcGill University · CA

Funding

MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)UL1RR024986 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHANLEY, THOMAS P. · 2007 to 2011
$51.2M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
IMPROVING PREDICTION OF IDDMR01DK053456 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HERMAN, MARK A, REDONDO, MARIA JOSE · 1999 to 2021
$9.5M
EPIDEMIOLOGY OF ISLET CELL AUTOIMMUNITY IN NIDDMR01DK056200 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIETROPAOLO, MASSIMO T · 2001 to 2009
$3.5M
NCATS NIH HHS UL1 TR000433NCRR NIH HHS UL1 RR024986NCRR NIH HHS UL1RR024986NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30DK020572NIDDK NIH HHS P30 DK092926NIDDK NIH HHS P30DK092926NIDDK NIH HHS R01 DK053456NIDDK NIH HHS R01 DK056200NIDDK NIH HHS R01 DK53456NIDDK NIH HHS R01 DK56200
6 · The paper itself

Abstract

Type 1 diabetes mellitus (T1DM) is an autoimmune disease arising through a complex interaction of both genetic and immunologic factors. Similar to the majority of autoimmune diseases, T1DM usually has a relapsing remitting disease course with autoantibody and T cellular responses to islet autoantigens, which precede the clinical onset of the disease process. The immunological diagnosis of autoimmune diseases relies primarily on the detection of autoantibodies in the serum of T1DM patients. Although their pathogenic significance remains uncertain, they have the practical advantage of serving as surrogate biomarkers for predicting the clinical onset of T1DM. Type 1 diabetes is a polygenic disease with a small number of genes having large effects (i.e. HLA), and a large number of genes having small effects. Risk of T1DM progression is conferred by specific HLA DR/DQ alleles [e.g., DRB1*03-DQB1*0201 (DR3) or DRB1*04-DQB1*0302 (DR4)]. In addition, HLA alleles such as DQB1*0602 are associated with dominant protection from T1DM in multiple populations. A discordance rate of greater than 50% between monozygotic twins indicates a potential involvement of environmental factors on disease development. Viral infections may play a role in the chain of events leading to disease, albeit conclusive evidence linking infections with T1DM remains to be firmly established. Two syndromes have been described in which an immune-mediated form of diabetes occurs as the result of a single gene defect. These syndromes are termed autoimmune polyglandular syndrome type I (APS-I) or autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), and X-linked poyendocrinopathy, immune dysfunction and diarrhea (XPID). These two syndromes are unique models to understand the mechanisms involved in the loss of tolerance to self-antigens in autoimmune diabetes and its associated organ-specific autoimmune disorders. A growing number of animal models of these diseases have greatly helped elucidate the immunologic mechanisms leading to autoimmune diabetes.

Indexed as

AutoantibodiesCation Transport ProteinsDiabetes Mellitus, Type 1Genetic Predisposition to DiseaseGlutamate DecarboxylaseHumansImmunity, CellularImmunity, HumoralMajor Histocompatibility ComplexZinc Transporter 8AutoantibodiesCation Transport ProteinsGlutamate DecarboxylaseICA512 autoantibodySLC30A8 protein, humanZinc Transporter 8GeneticsImmunologyPathogenesisType 1 diabetes

Identifiers

PMID25579746
PMCPMC4548800
OpenAlexW2023957762

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.